Literature DB >> 27097298

Hepatitis C-A clinical review.

Lan S Wang1, Lionel S D'Souza2, Ira M Jacobson2.   

Abstract

With an estimated prevalence of about 170 million people worldwide, chronic hepatitis C is an important cause of chronic liver disease associated with a substantial risk of cirrhosis and hepatocellular carcinoma. The recent past has borne witness to remarkable advancements in the treatment of chronic hepatitis C with the development of novel, effective, and well tolerated medications that have resulted in paradigm shifts in treatment approaches and may potentially affect the natural history of the disease. We provide a clinical review of current concepts and future developments in the management of chronic hepatitis C to aid in the understanding and individualization of chronic hepatitis C treatment. J. Med. Virol. 88:1844-1855, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  anti-hepatitis C virus directly acting antivirals; hepatitis C virus; public policy

Mesh：

Substances：

Year:  2016        PMID： 27097298     DOI： 10.1002/jmv.24554

Source DB:  PubMed          Journal:  J Med Virol        ISSN： 0146-6615            Impact factor:   2.327


  14 in total

1.  Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.

Authors:  Qiang Ding; Markus von Schaewen; Gabriela Hrebikova; Brigitte Heller; Lisa Sandmann; Mario Plaas; Alexander Ploss
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

2.  2'-C-methylated nucleotides terminate virus RNA synthesis by preventing active site closure of the viral RNA-dependent RNA polymerase.

Authors:  Alyson K Boehr; Jamie J Arnold; Hyung S Oh; Craig E Cameron; David D Boehr
Journal:  J Biol Chem       Date:  2019-10-01       Impact factor: 5.157

3.  Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen.

Authors:  Andrew Trigg; Eric Chan; Helen Kitchen; Tom Willgoss; Kai Fai Ho; Renee Pierson; Jane Scott
Journal:  J Health Econ Outcomes Res       Date:  2019-02-18

Review 4.  Viral Oncology: Molecular Biology and Pathogenesis.

Authors:  Uyen Ngoc Mui; Christopher T Haley; Stephen K Tyring
Journal:  J Clin Med       Date:  2017-11-29       Impact factor: 4.241

Review 5.  Significance of functional disease-causal/susceptible variants identified by whole-genome analyses for the understanding of human diseases.

Authors:  Yuki Hitomi; Katsushi Tokunaga
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2017       Impact factor: 3.493

6.  Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.

Authors:  Shinya Sato; Kei Moriya; Masanori Furukawa; Soichiro Saikawa; Tadashi Namisaki; Mitsuteru Kitade; Hideto Kawaratani; Kosuke Kaji; Hiroaki Takaya; Naotaka Shimozato; Yasuhiko Sawada; Kenichiro Seki; Koh Kitagawa; Takemi Akahane; Akira Mitoro; Yasushi Okura; Junichi Yamao; Hitoshi Yoshiji
Journal:  Clin Mol Hepatol       Date:  2019-02-25

Review 7.  Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C.

Authors:  Lindsey M Childs-Kean; Natalie A Brumwell; Emma F Lodl
Journal:  Infect Drug Resist       Date:  2019-07-23       Impact factor: 4.003

8.  Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.

Authors:  Kao-Chi Chang; Shui-Yi Tung; Kuo-Liang Wei; Chen-Heng Shen; Yung-Yu Hsieh; Wei-Ming Chen; Yi-Hsing Chen; Chun-Hsien Chen; Chi-Wei Yen; Huang-Wei Xu; Wei-Lin Tung; Chao-Hung Hung; Sheng-Nan Lu; Te-Sheng Chang
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

9.  Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden.

Authors:  P Frisk; K Aggefors; T Cars; N Feltelius; S A Loov; B Wettermark; O Weiland
Journal:  Eur J Clin Pharmacol       Date:  2018-04-09       Impact factor: 2.953

10.  Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals.

Authors:  Kazunori Yoh; Hiroki Nishikawa; Hirayuki Enomoto; Akio Ishii; Yoshinori Iwata; Yuho Miyamoto; Noriko Ishii; Yukihisa Yuri; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Ryo Takata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Nutrients       Date:  2017-10-18       Impact factor: 5.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.